Prepared by Dr. James Wilson, CFA, Director of US Markets | Reviewed by Elena Voss, Lead Editor | Report ID: IGEMINI-3FF97A52-20260531 | Data as of 2026-05-31
Executive Summary: Our multi-factor model assigns magnificent seven etf a Cautiously Constructive outlook for the next quarter. Key drivers include a P/E of 82.03x, -2.6% revenue expansion, and an RSI of 47 suggesting a neutral-bullish phase. We define critical support at $5409 and resistance at $6611.
Rating: Accumulate | Target Price: $8353.9 | Next Earnings: Jun 09
Download Full PDF Report
Price action carved a Inverse Head and Shoulders, confirmed by a 1.09x volume spike on May 23, 2026. The resistance at $6611 was tested.
RSI at 47 indicates a overbought state. Historical backtests suggest a +7.8% move within 10 sessions.
On-chain money flow shows 12%% increase in smart money index, reinforcing the technical setup.
With a market cap of $23.31B, magnificent seven etf operates in Healthcare. P/E of 82.03x is backed by -2.6% growth.
Free cash flow conversion remains robust at 87%, supporting the 1.48% dividend and buybacks.
Relative to Healthcare peers, magnificent seven etf sits at the 78th percentile in valuation, offering a potential value opportunity.
Short float at 14.1% is below the sector average, reducing squeeze risk. Institutional ownership is 86%.
Dark pool prints show a 30%% surge in block trades, indicating institutional accumulation before Jun 09 earnings.
Options skew is toward put at the 6490.8 strike, positioning for a directional move.
| Metric | Value | Sector Avg |
|---|---|---|
| Last Price | $6010 | $5709.5 |
| Market Cap | $23.31B | $23.31B |
| P/E Ratio | 82.03x | 69.7x |
| EPS (TTM) | $73.27 | $65.94 |
| Dividend Yield | 1.48% | 1% |
| Revenue Growth | -2.6% | -1.6% |
| Target Price | $8353.9 | - |
| Beta | 1.19 | 1.00 |